ACADIA Pharmaceuticals (ACAD) – Research Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) in the last few weeks:

• 6/30/2026 – ACADIA Pharmaceuticals was downgraded by HC Wainwright from “buy” to “neutral”.
• 6/30/2026 – ACADIA Pharmaceuticals had its price target raised by Bank of America Corporation from $29.00 to $30.00. They now have a “buy” rating on the stock.
• 6/29/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $37.00 price target on the stock.
• 6/29/2026 – ACADIA Pharmaceuticals had its price target raised by Citigroup Inc. from $32.00 to $35.00. They now have a “buy” rating on the stock.
• 6/29/2026 – ACADIA Pharmaceuticals had its price target raised by Canaccord Genuity Group Inc. from $32.00 to $36.00. They now have a “buy” rating on the stock.
• 5/8/2026 – ACADIA Pharmaceuticals had its price target lowered by Citigroup Inc. from $33.00 to $32.00. They now have a “buy” rating on the stock.

Insider Activity

In related news, insider James Kihara sold 5,401 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total transaction of $114,393.18. Following the completion of the sale, the insider directly owned 24,509 shares in the company, valued at $519,100.62. This represents a 18.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Mark C. Schneyer sold 3,506 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $21.79, for a total value of $76,395.74. Following the transaction, the executive vice president owned 66,145 shares in the company, valued at approximately $1,441,299.55. The trade was a 5.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 13,978 shares of company stock valued at $302,819. Company insiders own 26.20% of the company’s stock.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.